Latest Breaking News On - Stijn van rompay - Page 9 : comparemela.com

Hyloris shareholders approve all resolutions at the Annual General Meeting

Hyloris shareholders approve all resolutions at the Annual General Meeting
itbusinessnet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from itbusinessnet.com Daily Mail and Mail on Sunday newspapers.

Sven watthyJean luc vandebroekStijn van rompayInvestor relations communicationsHyloris pharmaceuticals sa euronext brusselsHyloris pharmaceuticalsInside informationEuronext brusselsAnnual general meetingVan rompayLuc vandebroekInvestor relations

Hyloris shareholders approve all resolutions at the Annual General Meeting

Jean luc vandebroekSven watthyStijn van rompayHyloris pharmaceuticals sa euronext brusselsHyloris pharmaceuticalsInvestor relations communicationsInside informationEuronext brusselsAnnual general meetingVan rompayLuc vandebroekInvestor relations

Hyloris has been granted EUR 1 million in non-dilutive funding from the Walloon Region

Regulated Information - Liège, Belgium – 08 June 2023 – 6 PM CET – Hyloris Pharmaceuticals SA , a specialty biopharma company committed to addressing unmet medical. | June 8, 2023

Waals gewestWalloon regionStijn van rompaySven watthyWilly borsusJean luc vandebroekHyloris pharmaceuticals sa euronext brusselsHyloris pharmaceuticalsInvestor relations communicationsTerritorial developmentEuronext brusselsForeign tradeVan rompayChief executive officerInnovation willy borsusLuc vandebroek

Hyloris announces submission of Maxigesic® IV packaging

Additional extractable & leachable data generated by an accredited lab facility located in North AmericaResults analyzed and evaluated by toxicological.

United statesSven watthyStijn van rompayJean luc vandebroekHyloris pharmaceuticals sa euronext brusselsHyloris pharmaceuticalsFood drug administrationInvestor relations communicationsHikma pharmaceuticalsEuronext brusselsDrug administrationComplete response letterVan rompayChief executive officerLuc vandebroekInvestor relations

Hyloris announces submission of Maxigesic® IV packaging data requested by the US FDA

Additional extractable & leachable data generated by an accredited lab facility located in North AmericaResults analyzed and evaluated by toxicological expertsPotential regulatory approval for. | April 18, 2023

United statesStijn van rompaySven watthyJean luc vandebroekHyloris pharmaceuticalsInvestor relations communicationsHikma pharmaceuticalsHyloris pharmaceuticals sa euronext brusselsFood drug administrationEuronext brusselsDrug administrationComplete response letterVan rompayChief executive officerLuc vandebroekInvestor relations